COVID Cancer Trial

  • by Charlotte Rawcliffe
  • 23-Oct-2020 12:00

The LCTC are managing a new project to assess the impact of COVID-19 on people with cancer.

The LCTC are managing a new project to assess the impact of COVID-19 on people with cancer.

People with cancer are among those at higher risk of COVID-19 complications, as cancer and its treatment can weaken the immune system. In addition, there has been disruption to cancer diagnosis and treatment because of the pandemic.

The Clinical Characterisation Protocol (CCP) CANCER-UK project will run over 12 months and will examine questions that are important for the care of patients with cancer. The study will also determine COVID-19 infection and mortality rates in people with different types of cancer, as well as those receiving different treatments, by collecting and analysing patient data.

This study is a companion to the highly successful UK arm of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Coronavirus Clinical Characterisation Consortium (ISARIC4C), which is led by researchers from Liverpool, Edinburgh and Imperial College London. ISARIC4C has collected data from 79,000 patients in the UK with COVID-19, around 9% of whom also have cancer. With almost 7,000 patients with both confirmed cancer and COVID-19 diagnoses already enrolled, it will be one of the largest and most detailed studies in the world.

CCP CANCER-UK is being led by Professor Carlo Palmieri, Professor in Translational Oncology at the University of Liverpool and Consultant in Medical Oncology at The Clatterbridge Cancer Centre, and Dr Lance Turtle, Senior Clinical Lecturer at the University of Liverpool and Consultant in Infectious Diseases at Liverpool University Hospitals, in collaboration with ISARIC4C.

The study has received £340,000 from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), with additional funding from The Clatterbridge Cancer Charity.

The Clatterbridge Cancer Centre NHS Foundation Trust is the sponsor for the study, which will be managed by the Liverpool Clinical Trials Centre (LCTC) with support from the Liverpool Experimental Cancer Medicine Centre.

Author: Charlotte Rawcliffe
Categories: Trial Related
Tags: Cancer,COVID-19
Share this article
Other news
Professor Carrol Gamble appointed NIHR Senior Investigator

Professor Carrol Gamble, Director of the Liverpool Clinical Trials Centre, has been appointed as a National Institute of Health Research (NIHR) Senior Investigator

Professor Michael Jenkinson appointed as Sir John Fisher / Royal College of Surgeons of England (RCS) Chair of Surgical Trials in Liverpool

Michael Jenkinson, Professor of Neurosurgery, from the University of Liverpool has been appointed into the highly prestigious position of Sir John Fisher / RCS Chair of Surgical Trials in Liverpool.

Prestigious International Award for LCTC Investigator

Professor Paula Ghaneh has been awarded the Hirshberg Foundation Award for the Best Paper.

Torpedo-CF - a major national study in cystic fibrosis - results published

New trial results will reduce hospital admissions for patients with cystic fibrosis